EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

A multicenter registry study of the CD38 antibody daratumumab for the treatment of microvascular inflammation following kidney transplantation

Thomas Drasch, Katharina A Mayer, Georg A Böhmig, Aylin Akifova, Fabian Halleck, Klemens Budde, David Rohlfing, Christian Hinze, Malte Kluger, Florian Grahammer, Jan Kowald, Sebastian Baatz und 10 weitere

Kidney International · 2026-11 · 110 (5) · 1262-1270

DOI: 10.1016/j.kint.2026.06.033 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Kidney International, 2026-11. Verfasst von Thomas Drasch und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, University Hospital Regensburg, Regensburg, Germany. Hauptthemen laut MEDLINE: Kidney Transplantation, Antibodies, Monoclonal, Graft Rejection, ADP-ribosyl Cyclase 1. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Microvascular inflammation (MVI) on kidney biopsy is associated with reduced graft survival following kidney transplantation (KT). CD38-targeting regimens, including the monoclonal antibody daratumumab, have recently emerged as a promising therapeutic strategy to counteract MVI and stabilize graft function. METHODS: Here, we retrospectively collected data on eGFR, albuminuria, kidney allograft pathology, donor specific antibodies (DSA) and donor-derived cell-free DNA (dd-cfDNA) levels from 70 KT patients both prior to and after initiation of daratumumab treatment. Safety signals were also documented. RESULTS: The study cohort consisted of 59 patients diagnosed with antibody mediated rejection (AMR) and 11 patients showing DSA- and C4d-negative MVI. Median time between transplantation and diagnosis of MVI was 36 months. Daratumumab treatment was initiated at a median of 1.6 months following diagnosis of MVI. A mixed linear model showed stabilization of eGFR from -1.6 ml/min/1.73m2/month in the year prior to the diagnosis of MVI to +0.3 ml/min/1.73m2/month after starting daratumumab. Six patients lost their graft during follow-up. Median albuminuria and dd-cfDNA levels decreased early during treatment, whereas the effect on DSA was heterogeneous. Both the number of doses and treatment duration had no measurable impact on outcome. CONCLUSIONS: Our preliminary data suggest efficacy of daratumumab in stabilizing kidney function in KT recipients with MVI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationAntibodies, MonoclonalGraft RejectionADP-ribosyl Cyclase 1Membrane GlycoproteinsHumansFemaleMaleMiddle AgedRetrospective StudiesAdultKidneyRegistriesGraft SurvivalMicrovesselsAllograftsTreatment OutcomeBiopsyGlomerular Filtration RateAged

Stichwörter der Autor:innen

antibody-mediated rejectiondaratumumabdd-cfDNAkidney transplantationmicrovascular inflammationoutcome

Substanzen

Antibodies, MonoclonaldaratumumabADP-ribosyl Cyclase 1Membrane GlycoproteinsCD38 protein, human

Autor:innen und Institutionen

  • Department of Nephrology, University Hospital Regensburg, Regensburg, Germany.
  • Department of Medicine III, Medical University of Vienna, Vienna, Austria.
  • Department of Nephrology and Intensive Care, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany.
  • III. Department of Medicine and Hamburg Center for Kidney Health, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Division of Nephrology, Department of Endocrinology, Nephrology, and Rheumatology, University of Leipzig Medical Center, Leipzig, Germany.

Zitieren

APA

Drasch, T., Mayer, K. A., Böhmig, G. A., Akifova, A., Halleck, F., Budde, K., Rohlfing, D., Hinze, C., Kluger, M., Grahammer, F., Kowald, J., Baatz, S., Reuter, S., Kemmner, S., Seibt, T., Pigorsch, M., Beck, J., Bornemann-Kolatzki, K., Schütz, E., …, & Zecher, D. (2026). A multicenter registry study of the CD38 antibody daratumumab for the treatment of microvascular inflammation following kidney transplantation. Kidney International, 110(5), 1262-1270. https://doi.org/10.1016/j.kint.2026.06.033

Vancouver

Drasch T, Mayer KA, Böhmig GA, Akifova A, Halleck F, Budde K, et al. A multicenter registry study of the CD38 antibody daratumumab for the treatment of microvascular inflammation following kidney transplantation. Kidney International. 2026;110(5):1262-1270. doi:10.1016/j.kint.2026.06.033

BibTeX
@article{Drasch2026,
  author = {Drasch, Thomas and Mayer, Katharina A and Böhmig, Georg A and Akifova, Aylin and Halleck, Fabian and Budde, Klemens and Rohlfing, David and Hinze, Christian and Kluger, Malte and Grahammer, Florian and Kowald, Jan and Baatz, Sebastian and Reuter, Stefan and Kemmner, Stephan and Seibt, Tobias and Pigorsch, Mareen and Beck, Julia and Bornemann-Kolatzki, Kirsten and Schütz, Ekkehard and Oellerich, Michael and Banas, Bernhard and Zecher, Daniel},
  title = {A multicenter registry study of the CD38 antibody daratumumab for the treatment of microvascular inflammation following kidney transplantation},
  journal = {Kidney International},
  year = {2026},
  volume = {110},
  number = {5},
  pages = {1262--1270},
  doi = {10.1016/j.kint.2026.06.033}
}
Kostenlos starten →